CoChat

Economic Implications of Treatment-Resistant Depression Among Employees

Greenberg, Paul, Corey-Lisle, Patricia K, Birnbaum, Howard, Marynchenko, Maryna, Claxton, Ami · 2004 · PharmacoEconomics

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Abstract

Background Conservative estimates indicate between 10% and 20% of all individuals with major depressive disorders (MDDs) fail to respond to conventional antidepressant therapies. Amongst those with MDD, individuals with treatment-resistant depression (TRD) have been found to be frequent users of healthcare services and to incur significantly greater costs than those without TRD. Given the prevalence of the disorder, it is understandable that MDDs are responsible for a significant amount of both direct and indirect healthcare costs. Objective To provide empirical findings for employees likely to have TRD based on analysis of employer claims data, in the context of previous research. Methods We conducted a claims data analysis of employees of a large national (US) employer. The data source consisted of medical, pharmaceutical and disability claims from a Fortune 100 manufacturer for the years 1996-1998 (total beneficiaries >100000). The employee sample included individuals with medical or disability claims for MDDs (n = 1692). A treatment pattern algorithm was applied to classify MDD patients into TRD-likely (n = 180) and TRD-unlikely groups. Treated prevalence of select comorbid conditions and the patient costs (direct and indirect) from the employer perspective by condition were compared among TRD-likely and TRD-unlikely employees, and with a 10% random sample of the overall employee population for 1998. Results The average annual cost of employees considered TRD-likely was d…

Overview

Integrity signals

Registry

Crossref · 10.2165/00019053-200422060-00003

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 32 references

Research works printed but not linked: 8

  1. Greenberg, 1993, J Clin Psychiatry, 54, 405
  2. 2000, Am J Psychiatry, 157, 1
  3. Mitchell, 1997, Am J Manag Care, 3, 323
  4. Thompson, 1996, Am J Manag Care, 2, 1239
  5. Sclar, 1994, Clin Ther, 16, 715
  6. Browne, 1998, Drug Benefit Trends, 33-, 42
  7. Burton, 1998, Dis Manag Health Outcomes, 2, 17
  8. Barnett, 2000, Am J Manag Care, 6, 1243

Cited by

See all 113

Metadata

Authors
Greenberg, P., Corey-Lisle, P. K., Birnbaum, H., Marynchenko, M., & Claxton, A.
Affiliations
  • Analysis Group (United States) (US)
  • Pharmaceutical Product Development (United States) (US)
Corresponding author
Greenberg, Paul
Venue
PharmacoEconomics
Published
2004
Volume
22
Issue
6
Pages
363-373
ISSN
1170-7690 (ISSN-L)
OpenAlex
W1971622512
Cited by
113
References
32
Citations by year
2025: 3 · 2024: 3 · 2023: 4 · 2022: 6 · 2021: 5 · 2020: 7 · 2019: 9 · 2018: 3 · 2017: 4 · 2016: 5 · 2015: 6 · 2014: 2 · 2013: 10 · 2012: 8
FWCI
3.34
Type
journal article
Language
en
Open access
closed
Locations
  • PharmacoEconomics (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
Keywords
treatment-resistant depression, major depressive disorder, health care costs, work loss costs, comorbidities, disability claims
MeSH terms
Adult, Aged, Antidepressive Agents, Depressive Disorder, Major, Major Depressive Disorder, Female, Health Benefit Plans, Employee, Humans, Male, Middle Aged, United States, Comorbidity, Prevalence, Treatment Failure, Economics, Pharmaceutical

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Economic Implications of Treatment-Resistant Depression Among Employees. https://app.cochat.ai/papers/10.2165/00019053-200422060-00003
The paper
Greenberg, P., Corey-Lisle, P. K., Birnbaum, H., Marynchenko, M., & Claxton, A. (2004). Economic Implications of Treatment-Resistant Depression Among Employees. PharmacoEconomics. https://doi.org/10.2165/00019053-200422060-00003

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.